AbbVie's Ubadacitinib Receives FDA and EMA Approval for Vitiligo Treatment AbbVie has submitted an application for the approval of ubadacitinib as a treatment for adults and adolescents with vitiligo, marking a potential breakthrough in autoimmune disease therapy.

AbbVie's Ubadacitinib Receives FDA and EMA Approval for Vitiligo Treatment #United_States #AbbVie #North_Chicago #Vitiligo #Ubadacitinib